NDI-091143
Potent allosteric ATP-citrate lyase inhibitor / Potent (IC50 = 2.1 nM ADP-Glo assay; 4.8 nM Oxaloacetate coupled enzyme assay) allosteric inhibitor of ATP-citrate lyase.1 NDI-091143 suppressed growth and clonogenic ability in thyroid cancer cell lines FTC-133 and 8505C.2 It also synergistically potentiated the cytotoxicity of sorafenib.2
Biochemicals & reagents
2375840-87-0
1) Wei et al. (2019), An allosteric mechanism for potent inhibition of human ATP-citrate lyase; Nature, 568 566 2) Huang et al. (2022), ACLY inhibitors induce apoptosis and potentiate cytotoxic effects of sorafenib in thyroid cancer cells; Endocrine, online ahead of print
-20°C
PATHWAY: Proliferation; Fatty acid metabolism -- RESEARCH AREA: Cell death -- DISEASE AREA: Cancer